Evidence Library

Key finding: EC50 values of 85.7-192.4 µg/mL against SARS-CoV-2. Dual mechanism: inhibits initial replication + prevents viral entry. Non-cytotoxic to healthy cells.

Key finding: Clinical data supporting Camelyn as antiviral agent with broad-spectrum activity across multiple viral infections.

Key finding: Confirmed broad-spectrum antimicrobial activity via membrane disruption — effective against both bacterial and fungal pathogens.

Key finding: Significant pain reduction and increased range of motion when Camelyn was combined with ultrasound-assisted delivery.

Key finding: Demonstrated immunomodulatory support in oncology patients, establishing foundation for 155-patient longitudinal review.

Key finding: Confirmed anti-tumor activity through immune system activation rather than direct cytotoxic action on cancer cells.

Key finding: First evidence of immunomodulatory mechanism — tumor growth regression via NK cell activation in animal models.

Key finding: Showed reduced tumor induction rates in treated groups compared to controls.

Key finding: Documented quality-of-life improvements and immune parameter normalization in advanced cancer patients.

Key finding: Demonstrated tumor growth inhibition and enhanced immune response markers in treated subjects.

Key finding: Tumor cells showed altered proliferation rates while healthy cells remained unaffected — early evidence of selective action.

Key finding: Reversed T-cell depression and stimulated interferon production in both patient groups — evidence of broad immunomodulatory action.

Key finding: One of the earliest systematic studies establishing anti-tumor activity of Georgian honey extract. Foundation for all subsequent research.

Key finding: Demonstrated immune parameter improvement in leukemia patients through combined therapy approach.

Key finding: Significant increase in phagocyte activity observed — the body's frontline immune cells became measurably more active.

Key finding: Across 155 patients with advanced malignancies (colon, prostate, bladder, ovarian), demonstrated tumor regression and significant quality-of-life improvement via IL-2, IFN-γ, TNF-α cytokine activation.